GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Hanall Biopharma Co Ltd (XKRX:009420) » Definitions » Stock Based Compensation

Hanall Biopharma Co (XKRX:009420) Stock Based Compensation : ₩1,623 Mil (TTM As of Dec. 2023)


View and export this data going back to 1989. Start your Free Trial

What is Hanall Biopharma Co Stock Based Compensation?

Hanall Biopharma Co's Stock Based Compensation for the three months ended in Dec. 2023 was ₩301 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Dec. 2023 was ₩1,623 Mil.


Hanall Biopharma Co Stock Based Compensation Historical Data

The historical data trend for Hanall Biopharma Co's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hanall Biopharma Co Stock Based Compensation Chart

Hanall Biopharma Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Stock Based Compensation
Get a 7-Day Free Trial Premium Member Only Premium Member Only 507.68 794.30 1,616.64 1,874.72 1,623.21

Hanall Biopharma Co Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 481.08 472.86 543.63 306.01 300.70

Hanall Biopharma Co Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩1,623 Mil.


Hanall Biopharma Co Stock Based Compensation Related Terms

Thank you for viewing the detailed overview of Hanall Biopharma Co's Stock Based Compensation provided by GuruFocus.com. Please click on the following links to see related term pages.


Hanall Biopharma Co (XKRX:009420) Business Description

Traded in Other Exchanges
N/A
Address
12 Bongeunsa-ro 114-gil, Daewoong Building, 3rd Floor, Gangnam-gu, Seoul, KOR
Hanall Biopharma Co Ltd is a part of the healthcare sector. It is one of Korea's leading pharmaceutical companies and is focused on drug delivery, biotherapeutics, and new small molecule discovery. The company's scope comprises of ophthalmology, immunology, cardiovascular treatment and dermatology.

Hanall Biopharma Co (XKRX:009420) Headlines

No Headlines